PCSK9 and myocardial infarction: Using human recombinant PCSK9 in human platelets induced by ADP, thrombin, and collagen, they found that PCSK9 enhances platelet integrin αIIbβ3 activation, ATP release, P-selectin release from α-granules, and clot formation, resulting in platelet aggregation, microvascular obstruction, and eventually ischemic events that lead to MI [36].